Transcending Metabolic Acidosis: Lactate as an Epigenetic Signal Reprogramming Diabetes-Sepsis I

08 May 20264 min read0 viewsJournal Feed

GIST

Patients with diabetic sepsis exhibit a paradoxical state characterised by persistently elevated inflammatory cytokines and severely impaired antigen presentation, with substantially elevated mortality rates compared to non-diabetic patients. This review assesses the strength of evidence for lactate-epigenetic-immune dysfunction.

Immune cells from diabetic patients exhibit basal glycolytic activity 2–3 times higher than healthy controls. Blood lactate levels rise markedly during sepsis, exceeding 10 mmol/L in critically ill patients—50-80% higher than non-diabetics.

Hyperlactataemia states have been associated with activation of GPR81 receptors and induction of lactylation at histone H3K18. This modification selectively activates inflammatory genes while suppressing antigen-presentation pathways, thereby providing a molecular basis for the paradoxical coexistence of inflammation and immunosuppression observed clinically.

Preliminary clinical studies (n = 48) demonstrate a correlation between H3K18la levels and disease severity (r = 0.63). In addition, lactate clearance of <30% within 6 hours is associated with poor prognosis.

Current therapeutic evidence remains limited: dichloroacetic acid reduces serum lactate by 20-30% but shows no proven survival benefit; GPR81 modulators remain in development; GM-CSF may increase HLA-DR expression but demonstrates inconsistent effects on infection and mortality.

Clinical Editorial

Context and clinical paradox

Patients with diabetes who develop sepsis present a contradictory immune profile: sustained elevations in inflammatory cytokines alongside marked defects in antigen presentation, and higher mortality than non‑diabetic counterparts.

The review evaluates evidence linking elevated lactate to epigenetic reprogramming that could explain this paradox.

Design and scope of evidence reviewed

This is a narrative synthesis drawing on mechanistic studies, patient biomarker analyses, and small clinical cohorts.

Quantitative clinical trial evidence is limited; much inference derives from correlative human data and preclinical mechanistic findings.

Key mechanistic observations

Immune cells from individuals with diabetes show baseline glycolytic rates approximately two‑ to threefold above healthy controls.
Sepsis induces pronounced hyperlactataemia, often exceeding 10 mmol/L in critical illness, with diabetic patients showing 50–80% higher lactate elevations versus non‑diabetics.
Elevated lactate is associated with activation of the lactate receptor GPR81 and with histone lactylation at H3K18 (H3K18la).
H3K18la is reported to upregulate inflammatory gene programs while concomitantly downregulating antigen‑presentation pathways, providing a potential molecular mechanism for simultaneous inflammation and immunosuppression.

Clinical correlations and biomarkers

A preliminary cohort (n = 48) found H3K18la levels correlated with disease severity (r = 0.63).

Failure to clear lactate by ≥30% within 6 hours is associated with worse prognosis in observational data.

Therapeutic implications reviewed

Three target strategies are proposed: reduce lactate production via metabolic modulation, interrupt the GPR81–H3K18la signaling axis, and pursue immune‑phenotype‑guided personalized interventions.

Existing interventions—dichloroacetic acid, GPR81 modulators, and GM‑CSF—have limited or inconsistent outcome evidence; dichloroacetic acid lowers lactate but lacks demonstrated survival benefit.